TopoTarget enters collaboration agreement with Inhibox  

The Anglo-Danish company has entered a two year agreement with UK company Inhibox to use Inhibox's screening technology for anti-cancer lead identification

Biopharmaceutical company TopoTarget has entered a collaboration agreement with UK company Inhibox to use Inhibox's virtual screening technology for anti-cancer lead identification. The financial details of the two year agreement have not been disclosed.


Inhibox has a database of over 35 million drug-like molecules, which it will use to identify novel inhibitors of an enzyme which TopoTarget has chosen as a target for anti-cancer drug discovery. The work forms part of an exclusive research deal which gives TopoTarget the option to initiate further virtual screens of other interesting targets during the agreement period.


TopoTarget is an Anglo-Danish company founded in 2000 through a merger between the UK cell cycle company Profilix and the Danish oncology company TopoTarget. It is based in Symbion Science Park, Copenhagen, and Oxford, UK, and develops new and improved drugs for the treatment of cancer. The news is reported on Medicon Valley's website.


Link > TopoTarget

Link > Medicon Valley

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×